CRDF Earnings Date: Nov 5, 2026 (Estimated) — Cardiff Oncology, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CRDF's next earnings date?
Cardiff Oncology, Inc. (CRDF) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.14 on revenue of $81,429.
How did CRDF do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Cardiff Oncology, Inc. posted EPS of -$0.14 versus the -$0.12 estimate, a miss of 12.5%. Revenue was $104,000 against a $62,778 estimate. The stock's 1-day post-earnings move was -5.7%.
How much does CRDF stock move after earnings?
CRDF beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 12.4% (up or down) in the day after earnings.
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.12 | -0.14 | +12.50% | $104,000 | ❌ Miss | -5.67% | -15.61% | +15.24% |
| 2026-05-14 | Q1 2026 | -0.13 | -0.18 | -38.46% | $41,000 | ❌ Miss | -3.47% | +3.47% | -17.92% |
| 2026-02-24 | Q4 2025 | -0.19 | -0.11 | +42.11% | $243,000 | ✅ Beat | +12.35% | +11.18% | +1.76% |
| 2025-11-06 | Q3 2025 | -0.20 | -0.17 | +15.00% | $120,000 | ✅ Beat | -2.67% | -4.44% | +4.00% |
| 2025-07-29 | Q2 2025 | -0.19 | -0.21 | -10.53% | $121,000 | ❌ Miss | -24.77% | -22.36% | -34.44% |
| 2025-02-27 | Q4 2024 | -0.25 | -0.21 | +16.00% | $151,000 | ✅ Beat | +4.43% | -4.43% | -18.97% |
| 2024-11-07 | Q3 2024 | -0.27 | -0.25 | +7.41% | $165,000 | ✅ Beat | -24.69% | -30.56% | -40.34% |
| 2024-05-02 | Q1 2024 | -0.25 | -0.22 | +12.00% | $205,000 | ✅ Beat | -21.43% | -24.55% | -29.24% |
Showing last 8 quarters.